This is an experimental study without drug and device, non-profit, single-center.The general objective of the project is to study how the adaptive immune response evolvesagainst SARS-CoV-2 with repeated vaccination boosters and infections also in relation tothe evolution of variations. This study will be relevant to frail populations who are themain targets of repeated vaccinations. Our project will benefit from the availability ofa highly cohort characterized of vaccinated people, including cancer patients and elderlypeople, with prospective collection of samples for an in-depth evaluation of theevolution of the immune response with repeated exposure to doses of infection or vaccine.As part of the study, analyzes will be carried out on samples of patients enrolled in amanner prospective at the oncology departments of the IRCCS (Medical Oncology, Departmentof Radiotherapy advanced oncology and nuclear medicine) and elderly patients residing inretirement homes of the IRCCS. Patients will also be asked for consent to store anyresidual samples in the Tropica DITM Biobank.
Not Provided
Other: Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses
Whole blood and serum samples will be longitudinally collected at the moment of the
administration of the booster doses (T0) and three weeks after the booster doses (T1).
Possible further time points will be collected within 2 years, based on the National
recommended future vaccination regimens.
Biological samples will be used for the following exams:
- Cellular immunity characterization
- T- and B-cells Immunophenotype.
- Specific T-cell response.
- In vitro specific B-cells characterization.
- Antibody-dependent cellular cytotoxicity.
- Humoral response characterization
- Serology assays.
- Avidity assay.
- Neutralization assays with different SARS-CoV-2 variants.
- Presence of specific or cross-reactive antibodies for common hCoV.
- Genetic and epigenetic analysis
Cancer patients
Inclusion criteria:
- Age> 18 years.
- Solid tumor diagnosis [I, II, III, IV stage,].
- Vaccinated with anti-SARS-CoV-2 vaccine or/and having history of past SARS-CoV-2
infections.
- Signed informed consent.
Exclusion criteria
- Age < 18 years.
- Absence of signed informed consent.
Elderly subjects
Inclusion criteria:
- Age> 70 years.
- Vaccinated with anti-SARS-CoV-2 vaccine or/and having history of past SARS-CoV-2
infections.
- Signed informed consent.
Exclusion criteria
- Age < 70 years.
- Absence of signed informed consent.
IRCCS Sacro Cuore Don Calabria hospital
Negrar, Verona, Italy
Investigator: Chiara Piubelli
Contact: +390456013706
chiara.piubelli@sacrocuore.it
Not Provided